+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer



Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer



Cancer Immunology, ImmunoTherapy 53(6): 479-489



Prostate cancer refractory to hormonal manipulation requires new treatment modalities. In the present study we attempted to identify prostate stem cell antigen (PSCA)-derived peptides immunogenic in HLA-A2+ prostate cancer patients in order to develop peptide-based immunotherapy against hormone-refractory prostate cancer (HRPC). Eleven different PSCA-derived peptides, which were prepared based on the HLA-A2 binding motif, were examined to determine whether they would be recognized by cellular and humoral immune responses in 12 HLA-A2+ patients (11 with HRPC and 1 with non-HRPC). Among the PSCA-derived peptides, PSCA 7-15 and PSCA 21-30 peptides effectively induced HLA-A2-restricted peptide-specific and tumor-reactive cytotoxic T lymphocytes (CTLs) from peripheral blood mononuclear cells (PBMCs) of HLA-A2+ patients. The PSCA 21-30 peptide was capable of inducing peptide-specific CTLs in both cancer patients and healthy donors, whereas the PSCA 7-15 peptide was immunogenic in only cancer patients. Immunoglobulin G (IgG) reactive to the PSCA 21-30 peptide was detected in plasma of most patients and healthy donors, whereas IgG reactive to PSCA 7-15 was undetectable in all cases. These results indicate that the former peptide elicits both cellular and humoral immune responses in both patients and healthy donors, whereas the latter elicits only cellular responses in patients. These two PSCA peptides should be considered for use in clinical trials of immunotherapy for HLA-A2+ HRPC patients.

(PDF emailed within 0-6 h: $19.90)

Accession: 012173593

Download citation: RISBibTeXText

PMID: 14634796

DOI: 10.1007/s00262-003-0464-x


Related references

Prostate stem cell antigen: Identification of immunogenic peptides and assessment of reactive CD8+ T cells in prostate cancer patients. International Journal of Cancer 102(4): 390-397, 2002

Identification of parathyroid hormone-related protein-derived peptides immunogenic in human histocompatibility leukocyte antigen-A24+ prostate cancer patients. British Journal of Cancer 91(2): 287-296, July 19, 2004

A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients. Prostate 60(3): 205-213, 2004

Murine six-transmembrane epithelial antigen of the prostate, prostate stem cell antigen, and prostate-specific membrane antigen: prostate-specific cell-surface antigens highly expressed in prostate cancer of transgenic adenocarcinoma mouse prostate mice. Cancer Research 61(15): 5857-5860, 2001

Prostate-related antigen-derived new peptides having the capacity of inducing prostate cancer-reactive CTLs in HLA-A2+ prostate cancer patients. Oncology Reports 12(3): 601-607, 2004

Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38(1): 73-78, Jan 1, 1999

Outcome of patients with hormone-refractory prostate cancer: prognostic significance of prostate-specific antigen-doubling time and nadir prostate-specific antigen. Japanese Journal of Clinical Oncology 38(1): 36-42, 2008

Prostate cancer targeting motifs: expression of αν β3, neurotensin receptor 1, prostate specific membrane antigen, and prostate stem cell antigen in human prostate cancer cell lines and xenografts. Prostate 72(5): 523-532, 2012

Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24+ prostate cancer patients. Prostate 60(4): 273-281, 2004

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era. Journal of Urology 171(4): 1525-1528, 2004

Effect of prednisone on prostate-specific antigen in patients with hormone refractory prostate cancer. Urology 52(2): 252-256, 1998

Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer. Urology 51(1): 150-157, 1998

The use of prostate-specific antigen as a surrogate end point in the treatment of patients with hormone refractory prostate cancer. Urologic Clinics of North America 24(2): 433-437, 1997

Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer. Cancer Immunology, ImmunoTherapy 51(5): 263-270, 2002

Human antibodies targeting cell surface antigens overexpressed by the hormone refractory metastatic prostate cancer cells: ICAM-1 is a tumor antigen that mediates prostate cancer cell invasion. Journal of Molecular Medicine 87(5): 507-514, 2009